Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02169505 (Clinical Trial/ Brentuximab vedotin)

Study Title
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) (NCT02169505)

Trial Description
The goal of this clinical research study is to study the safety of brentuximab vedotin (also known as SGN-035; Adcetris®, Seattle Genetics)  in patients with Hodgkin lymphoma or anaplastic large cell lymphoma (ALCL) who have had an allogeneic stem cell transplant. Another goal of this study is to learn if brentuximab vedotin can help to prevent the disease from coming back.

This trial is sponsored by M.D. Anderson Cancer Center. [1]

Study Data

  • Condition: Lymphoma
  • Interventions:
  • Phase: II
  • Estimated Enrollment: 20
  • Start: May 2015
  • Estimated Primary Completion: May 2018
  • Last verified: June 2015

Study Schematic 

Screen Shot 2016-07-19 at 5.05.55 PM


Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar